| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,100 | - | - |
| - | - | 4,200 | ₹2 -33.33% | 4,1250% |
| - | - | 4,300 | ₹7.4 0% | 2500% |
| - | - | 4,400 | ₹5.55 -37.64% | 3,375-3.57% |
| - | - | 4,450 | ₹10.9 0% | 1,7500% |
| - | - | 4,500 | ₹11.05 -30.93% | 15,5007.82% |
| 3750% | ₹375.6 0% | 4,550 | ₹26.15 0% | 7500% |
| 7500% | ₹293.65 0% | 4,600 | ₹20.5 -26.78% | 15,500-0.8% |
| 7500% | ₹253.75 26.18% | 4,700 | ₹36.8 -29.5% | 32,50014.03% |
| 875-12.5% | ₹213.9 14.44% | 4,750 | ₹47.95 -31.05% | 3,75076.47% |
| 21,750-2.79% | ₹176.5 30.01% | 4,800 | ₹64.75 -27.12% | 40,375-2.12% |
| 11,750-34.26% | ₹145 31.34% | 4,850 | ₹82.4 -27.07% | 15,2504.27% |
| 52,625-4.53% | ₹115.8 32.34% | 4,900 | ₹105.85 -18.73% | 28,500-2.14% |
| 10,875-4.39% | ₹98 43.06% | 4,950 | ₹155.9 0% | 1,3750% |
| 92,62521.67% | ₹76.95 44.5% | 5,000 | ₹165.55 -15.9% | 30,1252.11% |
| 6,375-13.55% | ₹63.1 55.61% | 5,050 | ₹235.9 0% | 7500% |
| 39,625-6.48% | ₹45.55 46.93% | 5,100 | ₹229.55 -18.97% | 12,50011.11% |
| 2500% | ₹36.2 0% | 5,150 | ₹274.9 0% | 2500% |
| 31,5000.8% | ₹26.8 52.27% | 5,200 | - | - |
| 18,375-11.97% | ₹16.2 58.04% | 5,300 | ₹470 0% | 3750% |
| 6,7500% | ₹7.5 0% | 5,400 | ₹510 -3.77% | 250-33.33% |
| 1,125200% | ₹6 -21.05% | 5,450 | - | - |
| 10,12519.11% | ₹6.7 74.02% | 5,500 | - | - |
| 1,1250% | ₹4.4 0% | 5,550 | - | - |
| 6,375-1.92% | ₹3.25 58.53% | 5,600 | - | - |
| 6,000-7.69% | ₹2 48.14% | 5,700 | - | - |
| 8,1250% | ₹3 0% | 5,800 | ₹955 0% | 2500% |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
